Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03173924 · ClinicalTrials.gov registry record · Phase 2

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

A Phase 2 study of Prostate Cancer and Prostatic Neoplasms, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
96
Enrollment target
1
Study location

NCT03173924: Active Phase 2 study of Prostate Cancer and Prostatic Neoplasms, sponsored by National Cancer Institute (NCI).

NCT03173924 is a Phase 2 study of Prostate Cancer and Prostatic Neoplasms that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 96 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03173924, a Phase 2 study of Prostate Cancer and Prostatic Neoplasms, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

Background: Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer. Researchers think an experimental radiotracer called 18F-DCFPyL could find sites of cancer in the body. Objective: To see if 18F-DCFPyL can identify sites of prostate cancer in people with the disease. Eligibility: People ages 18 and older who have metastatic prostate cancer Design: Participants will be screened with: * Blood tests * Physical exam * Medical history Participants will be assigned to 1 of 2 groups based on their PSA. Participants will have 18F-DCFPyL injected into a vein. About 2 hours later they will have a whole-body Positron Emission Tomography/Computed Tomography (PET/CT). For the scan, they will lie on their back on the scanner table while it takes pictures of the body. This lasts about 50 minutes. On another day, participants will have 18F -NaF injected into a vein. About 1 hour later, they will have a whole-body PET/CT. Participants will be contacted 1 3 days later for follow-up. They may undergo PET/Magnetic Resonance Imaging (MRI) either after having a 18F-DCFPyL PET/CT, or in place of PET/CT imaging. A tube may be placed in the rectum. More coils may be wrapped around the outside of the pelvis. If the 18F-DCFPyL PET/CT is positive participants will be encouraged to undergo a biopsy of one of the tumors. The biopsy will be taken through a needle put through the skin into the tumor. Participants will be followed for 1 year. During this time researchers will collect information about their prostate cancer, such as PSA levels and biopsy results. About 4-6 months after scanning is completed, participants may have a tumor biopsy. The biopsy will be taken through a needle put through the skin into the tumor. ...

Primary Outcome

Accuracy of DCFPyL-PET/CT diagnostics

Conditions Studied

Prostate Cancer Prostatic Neoplasms Metastatic Prostate Cancer Prostatic Cancer Prostate Neoplasms

Interventions

  • DRUG 18F-FDG
  • DRUG 18F-NaF
  • DRUG 18F-DCFPyL

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2017-06-06
Est. Completion 2028-02-06
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT03173924 still lists

NCT03173924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower).

The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which 18F-FDG is the first listed.

NCT03173924 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03173924 about?

NCT03173924 is a clinical study titled "18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer". Background: Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer. Researchers think an experimental radiotracer called 18F-DCFPyL could find sites of cancer in the body. Objective: To see if 18F-DCFPyL can identify...

What is the current status of trial NCT03173924?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2017-06-06. Estimated completion is 2028-02-06.

What conditions does trial NCT03173924 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms, Metastatic Prostate Cancer, Prostatic Cancer, Prostate Neoplasms.

What interventions are being tested in trial NCT03173924?

The interventions under investigation include: 18F-FDG (DRUG), 18F-NaF (DRUG), 18F-DCFPyL (DRUG).

Who is sponsoring clinical trial NCT03173924?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03173924 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03173924's enrollment target sits among peer trials

96 351st of 735 higher than 385 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03173924, the US trial registry maintained by the National Library of Medicine. NCT03173924 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.